Payment overview · 2025
General Payments
$583.51
36 reported records · 9 companies
Healthcare provider profile · identity verified
James M Orrell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MARION, IN · NPI 1447220900
Verified facts
What the public records show
CMS Open Payments records show James M Orrell, M.D. received $583.51 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Mounjaro, Paxlovid, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 401 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $179.66 | 30.8% | 18 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $153.56 | 26.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $146.70 | 25.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.71 | 3.7% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18.49 | 3.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.39 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.49 | 3.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $13.93 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.58 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $583.51 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $153.56 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $146.70 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $104.08 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.58 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.18 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
200 | 66 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
401 | 109 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2127 | 646 |
| Metoprolol Succinate | Metoprolol Succinate | 1304 | 379 |
| Amlodipine Besylate | Amlodipine Besylate | 1215 | 369 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1161 | 311 |
| Losartan Potassium | Losartan Potassium | 1009 | 305 |
| Lisinopril | Lisinopril | 860 | 270 |
| Tramadol Hcl | Tramadol Hcl | 727 | 166 |
| Metformin Hcl | Metformin Hcl | 725 | 219 |
| Furosemide | Furosemide | 724 | 230 |
| Pantoprazole Sodium | Pantoprazole Sodium | 722 | 219 |
| Omeprazole | Omeprazole | 617 | 201 |
| Pravastatin Sodium | Pravastatin Sodium | 562 | 170 |
| Famotidine | Famotidine | 452 | 142 |
| Tamsulosin Hcl | Tamsulosin Hcl | 442 | 147 |
| Eliquis | Apixaban | 401 | 109 |
| Sertraline Hcl | Sertraline Hcl | 357 | 120 |
| Meloxicam | Meloxicam | 347 | 126 |
| Metoprolol Tartrate | Metoprolol Tartrate | 345 | 103 |
| Gabapentin | Gabapentin | 332 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 98 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 284 | 85 |
| Allopurinol | Allopurinol | 273 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 91 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 248 | 77 |
| Zolpidem Tartrate | Zolpidem Tartrate | 248 | 44 |
| Alprazolam | Alprazolam | 238 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 80 |
| Metformin Hcl Er | Metformin Hcl | 237 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 64 |
| Buspirone Hcl | Buspirone Hcl | 210 | 79 |
| Ozempic | Semaglutide | 202 | 44 |
| Jardiance | Empagliflozin | 200 | 66 |
| Montelukast Sodium | Montelukast Sodium | 198 | 63 |
| Carvedilol | Carvedilol | 192 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 191 | 55 |
| Spironolactone | Spironolactone | 186 | 53 |
| Potassium Chloride | Potassium Chloride | 179 | 66 |
| Bupropion Xl | Bupropion Hcl | 177 | 53 |
| Glimepiride | Glimepiride | 174 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 44 |
| Trazodone Hcl | Trazodone Hcl | 160 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 44 |
| Ezetimibe | Ezetimibe | 140 | 46 |
| Baclofen | Baclofen | 137 | 55 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 128 | 35 |
| Atenolol | Atenolol | 126 | 36 |
| Synthroid | Levothyroxine Sodium | 118 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 117 | 38 |
| Prednisone | Prednisone | 117 | 71 |
| Alendronate Sodium | Alendronate Sodium | 116 | 37 |
| Fenofibrate | Fenofibrate | 110 | 33 |
| Clonazepam | Clonazepam | 109 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 41 |
| Celecoxib | Celecoxib | 106 | 36 |
| Farxiga | Dapagliflozin Propanediol | 106 | 27 |
| Warfarin Sodium | Warfarin Sodium | 102 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 100 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | 28 |
| Simvastatin | Simvastatin | 92 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 91 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 87 | 29 |
| Benazepril Hcl | Benazepril Hcl | 82 | 23 |
| Mirtazapine | Mirtazapine | 82 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 26 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 78 | 36 |
| Nitroglycerin | Nitroglycerin | 78 | 57 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 23 |
| Meclizine Hcl | Meclizine Hcl | 77 | 33 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 77 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 74 | 58 |
| Lorazepam | Lorazepam | 73 | 15 |
| Estradiol | Estradiol | 71 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 23 |
| Donepezil Hcl | Donepezil Hcl | 68 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 20 |
| Naproxen | Naproxen | 59 | 24 |
| Nystatin | Nystatin | 59 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 23 |
| Memantine Hcl | Memantine Hcl | 57 | 15 |
| Januvia | Sitagliptin Phosphate | 56 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 24 |
| Glipizide Er | Glipizide | 54 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 54 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 17 |
| Valsartan | Valsartan | 50 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 12 |
| Xarelto | Rivaroxaban | 49 | 16 |
| Finasteride | Finasteride | 47 | 14 |
| Mounjaro | Tirzepatide | 46 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 25 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 43 | 13 |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 31 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Felodipine Er | Felodipine | 39 | 11 |
| Lovastatin | Lovastatin | 39 | 12 |
| Pregabalin | Pregabalin | 39 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 14 |
| Chlorthalidone | Chlorthalidone | 38 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 26 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | 14 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 33 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 13 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 18 |
| Valacyclovir | Valacyclovir Hcl | 29 | 13 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 19 |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Bumetanide | Bumetanide | 26 | 13 |
| Fluocinonide | Fluocinonide | 26 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | 11 |
| Cefdinir | Cefdinir | 24 | 23 |
| Cephalexin | Cephalexin | 24 | 20 |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Amoxicillin | Amoxicillin | 22 | 19 |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | 13 |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 11 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Metaxalone | Metaxalone | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Victoza 3-Pak | Liraglutide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $583.51 · 36 records | ABBVIE INC. | AIRSUPRA, Dexcom G6 Transmitter, FARXIGA, INJECTAFER, Kerendia, Korlym, MOUNJARO, PAXLOVID, QULIPTA, UBRELVY, VRAYLAR, Veozah, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error